




Fund Profile

Four Reasons to Invest in the AMIDEX Cancer Innovations & Healthcare Mutual Fund

- 1. Index methodology.**
We invest in an index of 45 stocks representing \$1.4 trillion of cancer drug, equipment and biotech companies.
- 2. Efficiency.**
One purchase gets you exposure to an array of cancer companies from newer, smaller cap biotech companies to established "blue chip" pharmaceutical companies. Avoids the need to buy separate biotech, pharmaceutical and medical device portfolios.
- 3. Balance.**
Half of the portfolio is invested in large cap pharmaceutical companies. The other half adds exposure to biotech and medical equipment companies.
- 4. Tax Considerations.**
Because it is an index fund, the AMIDEX Cancer Innovations & Healthcare Mutual Fund anticipates low portfolio turnover, and corresponding tax efficiency.

"The AMIDEX Cancer Innovations & Healthcare Mutual Fund includes three key Healthcare groups - pharmaceuticals, biotech, and medical equipment companies. A single investment gives you exposure to the industries at the core of the fight against cancer"

Portfolio Breakdown By Industry Group *



*Holdings and weights as of 6/30/09 and subject to change. The AMIDEX Cancer Innovations & Healthcare Mutual Fund is not diversified and is composed of only 45 companies. All investments are inherently subject to market risk. The relatively limited liquidity of some of the equities in the portfolio may effect the Fund's ability to acquire desired positions quickly or ability to dispose of securities at a desirable price and time.

Fund Overview 6/30/2009

Min. Initial Investment	\$500
Subsequent Investment	\$250
IRA Account	\$500
Portfolio Turnover	0.00%
Investment Style	Index
Fund Category	Mid Cap
Avg. Market Cap (b)	\$41.15

The Index Methodology
We don't try to "time" or "outguess" the market. Our index methodology results in lower portfolio turnover and potentially lower capital gain taxes.

AMIDEX Cancer Innovations & Healthcare Mutual Fund is a portfolio of AMIDEX Funds, Inc., an open-end registered investment company.


For more information about the Fund and other portfolios, please contact your financial adviser, call our sales desk, or visit us online at www.amidex.com.

AMIDEX
MUTUAL FUNDS

For a prospectus containing more information about the fund, contact your financial adviser or call our sales desk at (888) 876 - 3566

"The number of new cancer drugs in development has quadrupled during the last decade."

Number of New Cancer Drugs in Development



*Source: New medicines in development for cancer, PhRMA 1991-2003



Fund Profile

AMIDEX Cancer Innovations & Healthcare Mutual Fund Selected List of Holdings*

Gilead Sciences	GILD	5.10%
Celgene	CELG	3.47%
Johnson & Johnson	JNJ	3.43%
AstraZeneca	AZN	3.20%
Wyeth	WYE	2.74%
Biogen Idec	BIIB	2.59%
Genzyme	GENZ	2.33%
Novartis	NVS	2.22%
GlaxoSmithKline	GSK	2.13%
Varian Medical Systems	VAR	2.12%
Amgen	AMGN	2.08%
Pfizer	PFE	1.90%
Eli Lilly & Co	LLY	1.67%
Merck & Co.	MRK	1.35%

*Holdings and weights as of 6/30/09 and subject to change.

The AMIDEX Cancer Innovations & Healthcare Mutual Fund is not diversified and is composed of only 45 companies. All investments are inherently subject to market risk. The relatively limited liquidity of some of the equities in the portfolio may effect the Fund's ability to acquire desired positions quickly or ability to dispose of securities at a desirable price and time. The fund has a high industry concentration in healthcare securities, which could entail greater risk than a fund with more diversified holdings. For instance, market conditions, interest rates, or economic and regulatory developments can significantly affect an issuer, an industry, or even a group of related industries, more adversely than other securities in the market as a whole. These factors may affect the value of your investment.

For more information, contact your financial advisor or call toll free (888) 876 3566

Distributor: InCap Securities, Inc.
630-A Fitzwatertown Rd.
Willow Grove, PA 19403



AMIDEX Cancer Innovations & Healthcare Mutual Fund is a new way to invest in the stocks of companies that are developing the products and services needed to detect & fight cancer.

As of 2004, over 200 biotechnology drugs, most developed by private sector companies, have been approved for marketing. Many of the new products are safer and more effective than the older chemical compounds used for treatment.



A revolution is underway in the development of new and better cancer drugs. Our Fund invests in the companies at the forefront of these developments.



Expenditures by the private sector for research and development of new diagnostic tools and innovative treatments continue to grow. U.S. pharmaceutical companies will spend over \$33 billion this year on research and development.*

Today, almost 40% of all drugs in human clinical testing are cutting-edge drugs targeted at forms of cancer.

All of the companies in the Fund are in the Healthcare Sector. Investing in a single sector is riskier than investing in a variety of sectors. The companies in the Fund are subject to extensive regulation, which may change in a way adverse to the industry. This sector may be riskier than other market sectors.



Past performance does not guarantee future results. Portfolio holdings are subject to change. The Fund is not diversified. The Fund invests in foreign securities issuers that are domiciled in nations considered to have stable and friendly governments, but there is the possibility of expropriation, confiscation, taxation, currency blockage or political or social instability which could negatively affect the Fund. The Fund is not available to residents of all states. This material must be preceded or accompanied by a current AMIDEX Cancer Innovations & Healthcare Mutual Fund prospectus. Please read the prospectus carefully before investing or sending your money. Investment return and principal value will fluctuate, so that shares when redeemed, may be worth more or less than the original cost. This is not an offering, which can be made only by prospectus.